

Press release 2014-04-09

The European Patent Office issues decision to grant patent for Foxy-5

WntResearch AB today announces that the European Patent Office (EPO) has informed on their homepage that a Decision to grant a European patent for EP 2 384 763, covering WntResearch's important peptide Foxy-5, has been taken.

CEO Nils Brünner comments: "I am extremely satisfied that we are now having a European patent protection for our lead compound Foxy-5. It is especially gratifying to have this patent in place since it is our principal patent."

For additional information please contact:

Nils Brünner, VD

E-mail: nbr@wntresearch.com

Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.